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http://dx.doi.org/10.1016/j.ccr.2014.07.028SUMMARYDNA methylation in promoters is well known to silence genes and is the presumed therapeutic target of
methylation inhibitors. Gene body methylation is positively correlated with expression, yet its function is
unknown. We show that 5-aza-20-deoxycytidine treatment not only reactivates genes but decreases the
overexpression of genes, many of which are involved in metabolic processes regulated by c-MYC. Downre-
gulation is caused by DNA demethylation of the gene bodies and restoration of high levels of expression
requires remethylation by DNMT3B. Gene body methylation may, therefore, be an unexpected therapeutic
target for DNA methylation inhibitors, resulting in the normalization of gene overexpression induced during
carcinogenesis. Our results provide direct evidence for a causal relationship between gene bodymethylation
and transcription.INTRODUCTION
Genesilencingmediatedbyaberrant promoterDNAhypermethy-
lation isoneof thekey featuresof cancer (BaylinandJones,2011).
Although somatically heritable, the reversibility of DNA methyl-
ation by pharmacological interventions makes it an attractive
therapeutic target. Over the past few years, various DNAmethyl-
transferase inhibitors have been developed with the goal of reac-
tivating aberrantly silenced genes, andmany of themhave shown
encouraging results in both preclinical and clinical settings, high-
lighting the potential of epigenetic therapy (Azad et al., 2013;
Balch and Nephew, 2013; Yamazaki and Issa, 2013). Two DNA
methylation inhibitors, 5-Aza-2-deoxycytidine (5-Aza-CdR) and
5-azacytidine (5-Aza-CR), were discovered to have hypomethy-
lating activities at low concentrations (Jones and Taylor, 1980;
Taylor and Jones, 1979). Both drugs are cytosine analogs that
are incorporated into replicating DNA in place of cytosine and
trap DNA methyltransferases (DNMTs), resulting in proteosomal
degradation and heritable global demethylation as cells divideSignificance
Although promoter methylation is known to silences genes, i
relationship between gene body methylation and expressi
20deoxycytidine induces the demethylation of gene bodies an
rapid remethylation after drug treatment requires the DNMT3B
ation and altered expression. Therefore, gene body methylatio
could lead to the downregulation of oncogenes and metabolic
It has direct implications in understanding the responses of p
C(Kelly et al., 2010a). They have been approved by the Food and
Drug Administration (FDA) in the United States for the treatment
of myelodysplastic syndrome (MDS), a preleukemic disorder
(Kantarjian et al., 2006;Silvermanet al., 2002).More recently, clin-
ical trials have been initiated to investigate the possibility of ex-
tending their utilization to solid tumors, such as ovarian and
lung cancers, either alone or in combination with other drugs
(Azad et al., 2013; Juergens et al., 2011; Li et al., 2014; Matei
et al., 2012;Wrangle et al., 2013). Transientexposure to lowdoses
ofDNA-demethylating agents canexert durable antitumor effects
in solid tumors and long-term stability of demethylation of pro-
moter CpG islands (Kagey et al., 2010; Tsai et al., 2012).
Much effort has been invested to determine the molecular
mechanisms underlining the clinical efficacies of 5-Aza-CR and
5-Aza-CdR (Heyn and Esteller, 2012; Kelly et al., 2010a). Until
now, studies have been primarily confined to studying promoter
demethylation followed by subsequent gene reactivation. Previ-
ously, we have shown that the transcribed regions of genes are
heavily methylated and that the level of methylation is positivelyt has not yet been demonstrated whether there is a causal
on. We show that the DNA methylation inhibitor 5-aza-
d alters expression of the associated genes in cancer. The
showing a causal relationship between gene body methyl-
n could be a potential therapeutic target since its inhibition
genes that are commonly overexpressed in various cancers.
atients to FDA-approved DNA methylation inhibitor drugs.
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Figure 1. Transient 5-Aza-CdR Treatment Shows Prolonged Effects on Cell Growth and DNA Methylation
(A) PDT (left) for HCT116 cells after 5-Aza-CdR treatment (red) and vehicle treatment (black). The y axis denotes doubling time (hours); the x axis denotes time (in
days) after 5-Aza-CdR was withdrawn. Colony formation assay (right) for HCT116 cells at the indicated time points that the cells were seeded after the withdrawn
of 5-Aza-CdR. Colonies were stained 10 days after seeding.
(B) Smooth Kernel scatter plots showing global DNA methylation patterns after 5-Aza-CdR treatment and at the indicated time points after treatment. The x axis
indicates beta values for untreated control, and the y axis indicates beta values for 5-Aza-CdR-treated cells at indicated time points.
(C) Probes that were heavily methylated (beta value > 0.8) before 5-Aza-CdR treatment were classified, using consensus clustering, into four groups according to
their rates of demethylation and remethylation after treatment. The solid line is themedian value, while the dotted lines are the lower quartile (lower dotted line) and
the upper quartile (upper dotted line). Distribution of probes: locations of all probes on the 450K platform compared to probes in groups I to IV.
See also Figure S1.
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Salem et al., 2000). Recently, more detailed genome-wide
studies have also demonstrated that DNA methylation in tran-
scribed regions is correlated with gene expression (Kulis et al.,
2012; Maunakea et al., 2010; Varley et al., 2013). DNA methyl-
ation in transcribed regions could potentially silence alternative
promoters, retrotransposon elements, and other functional ele-
ments to maintain the efficiency of transcription (Kulis et al.,
2012; Maunakea et al., 2010; Varley et al., 2013; Wolff et al.,
2010). However, the potential for demethylation of gene bodies
induced by DNA methylation inhibitors to alter their expres-
sion does not seem to have been reported. In this study, we
investigated whether demethylation of gene bodies induced by
5-Aza-CdR could alter gene expression and possibly be a ther-
apeutic target in cancer.
RESULTS
Restoration of Cell Growth Rate after 5-Aza-CdR
Treatment Is Associated with Global Remethylation
Transient exposure of dividing cells to low doses of 5-Aza-CdR
or 5-Aza-CR leads to heritable increases in cell doubling time578 Cancer Cell 26, 577–590, October 13, 2014 ª2014 Elsevier Inc.that are gradually reversed on growth in the absence of further
drug treatment (Bender et al., 1999; Tsai et al., 2012). To inves-
tigate potential mechanisms for the drug’s prolonged effects,
we treated HCT116 cells transiently with low-dose (0.3 mM) 5-
Aza-CdR for 24 hr and maintained the cells in drug-free medium
until there were no further differences in the population doubling
times (PDT) of the control and 5-Aza-CdR-treated cells (Fig-
ure 1A). Drug treatment exerted an apparent biphasic effect on
the PDT of HCT116 cells. Soon after exposure, the PDT
increased from 26 to 38 hr and then decreased quickly from 5
to 23 days before more gradually reverting to the untreated level
around day 56 after drug treatment. The differences in growth
rates between treated and control cells completely disappeared
by day 77. Low-dose 5-Aza-CdR treatment also depressed the
abilities of HCT116 cells to form colonies when plated at low
density, even at day 42 after drug treatment (Figure 1A).
We thenmonitored long-term DNAmethylation changes using
the Illumina Infinium HumanMethylation450 (HM450) DNA me-
thylation array. This platform contains probes for 482,421 CpG
sites across the genome, covering 99% of RefSeq genes
(more than 21,000 genes) with an average of 17 CpG sites per
gene, and probes are distributed in promoters, gene bodies,
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demethylation of all methylated probes (the mean decrease in
beta value is 0.41) was observed at day 5 after drug treatment,
and most of the demethylated probes regained their original
methylation levels at day 68 in a time-dependent manner (Fig-
ure 1B). Using a beta value of 0.2 as a threshold for differential
DNA methylation between treated and mock-treated cells and
by examining heavily methylated probes in the controls (b >
0.8), we identified 188,631 probes as becoming demethylated
in HCT116 cells at day 5 (Figure 1B). At day 68, about 8% of
the probes (14,762) remained demethylated under the same
criteria. A positive correlation (r = 0.83) was apparent between
PDT differences and median DNA demethylation changes in
HCT116 cells after 5-Aza-CdR treatment (Figure S1A available
online), which suggested that DNA methylation changes might
determine cell growth recovery rate.
We next used consensus clustering to classify the behaviors of
the top 10% of the most variable, originally highly methylated
probes in the controls, using k-means = 4 to divide the probe
sets into fourgroupsaccording to their ratesof remethylationafter
treatment (Figure 1C). More than 3,000 probes, which were de-
methylated at day 5 and regained DNA methylation quickly after
drug withdrawal, were classified as group I probes. Their DNA
methylation levels were almost completely restored to baseline
at day 42. Alternatively, the 13,458 probes in group IV showed
the slowest rate of remethylation and remained demethylated at
day 42. Rates of remethylation of the group II probes (n = 4,099)
andgroup III probes (n=5,674)had intermediate remethylationki-
netics (Figure 1C) andwere not included in subsequent analyses.
Of the more than 21,000 total genes represented in the HM450
array, 34% (n=7,158)were included in these four groups.Groups
I–IV contain 1,507, 2,003, 2,657, and 3,990 genes, respectively,
some of which may overlap across the groups. We next studied
thegenomic locationsof theprobesspecified in theHM450anno-
tation by defining three categories of probes; those locatedwithin
1,500 base pairs (bp) upstream and downstreamof the transcrip-
tion start site (TSS200 and TSS1500, respectively) were called
‘‘promoter regions.’’ Probes located in transcribed regions
were called ‘‘gene bodies,’’ and the remainder was classified as
‘‘other.’’ About 80% of the probes that regained methylation in
a rapidmanner were located in gene bodies in group I, compared
to about 30% in group IV (Figure 1C), with intermediate kinetics
visible in groups II and III; the detailed probe distribution in
different groups were presented in Figure S1B.
Collectively, our data showed that 5-Aza-CdR induced imme-
diate and prolonged cell growth inhibition as well as a genome-
wide DNA demethylation immediately after treatment (see day
5 in Figure S1C). The recovery rate of cell growth and the rate
of global rebound DNA methylation were negatively correlated.
Furthermore, the remethylation rates of individual probes were
not uniform in that gene bodies were most rapidly remethylated,
and this might play a role in the prolonged effect of drug
treatment.
The Most Rapid Rebound Methylation Occurs in Gene
Bodies and Is Positively Correlated with Gene
Expression Levels
We next conducted genome-wide expression assays at the
same time points as those analyzed by the DNA methylationCassays. Separating group I probes by genomic location, we first
investigated the behaviors of the relatively small portion (less
than 5%) within this group that were located in promoter regions.
An enrichment peak of these probes (25/105, 24%) displayed the
expected negative correlation between DNA methylation and
gene expression (r <0.75) in the kernel density plot (Figure 2A).
Negatively correlated genes associated with these probes were
reactivated at day 5 and resilenced soon after treatment, and the
original DNA methylation levels were reestablished at day 14
(Figure 2A). We then studied the methylation status of these
negatively correlated probes in primary colorectal tumor sam-
ples and adjacent normal colonic tissues using The Cancer
Genome Atlas (TCGA) colon database (http://cancergenome.
nih.gov/). As shown in Figure 2B, approximately 50% of the
probes were hypermethylated in uncultured colon carcinomas,
while the other half of probes were methylated in both normal
and tumor samples. It is interesting that nearly all the probes
methylated in both normal and tumor samples were located
outside of CpG islands (Figure 2B), which is suggestive of tis-
sue-specific DNA methylation patterns. We also investigated
the expression of the negatively correlated probes by comparing
expression array data of 19 primary normal colonic tissues and
101 primary colon adenocarcinomas from the TCGA database
(Figure 2C). Eight out of 20 annotated genes were significantly
repressed in colon adenocarcinoma samples (p < 0.001). Taken
together, our data indicate that some of the fast rebounding
CpGs located in promoter regions are likely silenced by tumor-
specific DNA hypermethylation in primary tumors.
What is more interesting is that 80% of group I probes were
located in gene body regions, and about 20% of these exhibited
a positive correlation between DNA methylation and expression
(498/2,467 probes, 20%, r > 0.75) (Figures 1C, 2D, and S1B).
Their expression was reduced 5 days after 5-Aza-CdR treat-
ment, increased at day 14, and almost reverted to original levels
of both expression and DNAmethylation at day 42 (Figure 2D). In
addition, the positively correlated gene body CpGs were methyl-
ated in both primary normal and tumor colon tissues in the TCGA
colon data set (Figure 2E), and the majority of these are located
in non-CpG island regions (Figure 2E). It is surprising that a
large proportion of the positively correlated genes were overex-
pressed in primary tumor samples compared to normal colon tis-
sues (Figure 2F). Most of the promoter regions corresponding to
these body probes were not differentially methylated in normal
and uncultured tumor samples (Figure S2). Therefore, the over-
expression of the genes in cancer was not being driven by
DNA methylation changes in their promoters.
Slow-Rebounding Genomic Regions Are De Novo
Methylated in Primary Colon Tumors
Next, we investigated the group IV probes shown in Figure 1C
that displayed the slowest rates of rebound methylation com-
pared to the other three groups. Only 27% of probes in the slow-
est remethylation group were located in gene body regions,
whereas 24% were located in promoter regions. A set of 485
probes displayed an inverse correlation between DNA methyl-
ation and gene expression after 5-Aza-CdR treatment, and
these remained expressed for over 42 days, while their pro-
moters had sustainedDNAdemethylation (Figure 3A). In contrast
to the fast-rebounding promoter CpGs (Figure 2B), the majorityancer Cell 26, 577–590, October 13, 2014 ª2014 Elsevier Inc. 579
Figure 2. DNA Methylation and Gene
Expression of Fast Rebound Probes, in
Group I, in HCT116 Cells and Uncultured
Normal/Tumor Colon Samples
(A and D) Kernel density plots showing the cor-
relation between DNA methylation at the pro-
moter region (A) or gene body (D) and gene
expression in HCT116 cells. The x axis indicates
the Pearson correlation (r) between DNA methyl-
ation and gene expression for a given probe at all
the measured time points. The y axis indicates the
density of probes. Twenty-five of 105 probes (r <
0.75) at the promoter region showing a signifi-
cant inverse correlation between DNA methyl-
ation and gene expression are highlighted in pink
(A). Most of the probes in group I (2,467) are
located in gene bodies (D). Among them, the 498
probes at gene bodies that exhibited a positive
correlation between DNA methylation and gene
expression are highlighted in green (D). The small
windows in (A) and (D) represent the average
dynamic changes between DNA methylation (red,
Met.) and expression (green, Exp.) from the
shaded highlighted regions. The left y axis rep-
resents percentage of DNA methylation, and the
right y axis represents relative expression, while
the x axis represents times (from day 0 to day 42).
KS, Kernel smoothing density estimate.
(B and E). Supervised cluster analysis of DNA
methylation in TCGA colon samples using the
available probes identified in HCT116 (highlighted
by shading in A and D). Twenty of 25 are
available for (B), while 399 out of 498 are available
for (E). Green represents normal colon tissues
(n = 38); brown represents colon tumors (n = 258). Blue indicates low beta values; yellow indicates high beta values. CGI, CpG island.
(C and F). Oncomine expression data analysis of 101 colon cancer samples (brown) versus 19 normal colon samples (green). The genes correspond to the
probes identified in (B) and (E), 19 genes correspond to 25 probes in (A), and 210 genes correspond to 498 probes in (D). The expression data for genes was
downloaded from Oncomine (TCGA Colon Adenocarcinoma versus Normal set), and the heat maps generated based on TCGA expression for the indicated
groups. Blue denotes low expression, and red denotes high expression.
See also Figure S2.
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in primary colon cancers (319/423, 75%, p < 0.001) (Figure 3B)
and were also located within CpG islands (348/423 probes,
82%) in the TCGA data set (Figure 3B). Additionally, at least
57% of these genes had been silenced or downregulated in
TCGA colon tumor samples according to the Oncomine data-
base (Figure 3C).
On the other hand, 3,370 probes located in gene bodies dis-
played a multimodal distribution of correlation coefficients be-
tween DNA methylation and gene expression (Figure 3D). A
set of 494 probes showed a positive correlation with expression
(Figure 3D, right side), as had been observed in the fast-re-
bounding group (Figure 2D). Furthermore, less than half of these
probes had become de novo methylated in primary colon can-
cers (Figure 3G), and some corresponding genes were also
overexpressed in primary colon tumors (Figure 3H). In addition,
447 probes located in gene bodies were negatively correlated
with gene expression, despite their genomic location. Almost
half of these were methylated in primary colon tumors (Fig-
ure 3E), and 62% were located in CpG islands (Figure 3E).
Consistent with the DNA methylation data, the expression of
more than 90% of negatively correlated genes and probes
were also downregulated in colon cancers (Figure 3F). To un-580 Cancer Cell 26, 577–590, October 13, 2014 ª2014 Elsevier Inc.derstand why gene body DNA methylation and gene expres-
sion showed a negative correlation, we found that about 40%
of these inversely correlated gene body probes were associ-
ated with H3K4m1 and H2A.Z enrichment peaks in human
mammary epithelial cells (HMECs) (Encyclopedia of DNA Ele-
ments [ENCODE; https://genome.ucsc.edu/ENCODE/], chro-
matin immunoprecipitation sequencing [ChIP-seq] data). These
findings suggest that some of the probes located in gene
bodies may acutely represent functional elements, such as en-
hancers or alternative promoters under normal circumstances
(Figure S3).
Rapid Rebound DNA Methylation Requires DNMT3B
Wenext monitored global DNAmethylation and gene expression
profiles in two HCT116 derivative cell lines with genetic knock-
outs for DNMT3B (3BKO) or for DNMT1 (1KO) (Rhee et al.,
2000, 2002) to determine the specific DNMTs responsible for
restoring the demethylation after 5-Aza-CdR treatment. All
probes examined were the same in all three cell lines, and the
rates of remethylation were strongly retarded in 3BKO cells,
especially in the group I gene set (Figure 4A). Compared to the
wild-type cells, 5-Aza-CdR treatment strongly inhibited the
PDT of 3BKO cells at early time points, which is consistent
Figure 3. DNA Methylation and Gene Expression of Slow Rebound Probes, in Group IV, in HCT116 Cells and Normal/Tumor Colon Samples
(A and D) Kernel density plots show the correlation between DNAmethylation (promoter region in A and gene body in D) and gene expression in HCT116 cells. The
x axis indicates the Pearson correlation (r) between DNA methylation and gene expression for a given probe at all the measured time points. The y axis indicates
the density of probes. Four hundred eighty-five of 2,870 probes (r <0.75) show a significant inverse correlation between DNAmethylation and gene expression
(A). A similar number of probes in group IV (3,370) is located in gene bodies (D). Among them, 447 probes (left highlighted region in D) exhibit a negative correlation
between DNA methylation and gene expression, while 494 probes (right highlighted region in D) exhibit a positive correlation. The small windows in (A) and (D)
represent the average dynamic changes between DNA methylation (red, Met.) and expression (green, Exp.) from the shaded highlighted regions. The left y axis
represents percentage DNA methylation and the right y axis represents relative expression, while the x axis represents times (from day 0 to day 42). KS, Kernel
smoothing density estimate.
(B, E, andG). Supervised cluster analysis of DNAmethylation in TCGA colon samples using the available probes identified in HCT116 cells (highlighted by shading
in A and D). Four hundred twenty-three of 485 probes are available for (B), while 383 out of 447 probes (negative correlation) and 415 out of 494 (positive
correlation) are available for (E) and (G), respectively. Green represents normal colon tissues (n = 38); brown represents colon tumors (n = 258). Blue indicates low
beta values, and yellow indicates high beta values. CGI, CpG island.
(C, F, and H). Oncomine expression data analysis of 101 colon cancer samples (brown) versus 19 normal colon (green); regarding the genes corresponding to the
probes identified in (B), (E), and (G), 294 genes correspond to 485 probes in (A), and 209 genes correspond to 447 probes in (D), while 219 genes correspond to
494 probes in (D). The expression data for genes was downloaded from Oncomine (TCGA colon adenocarcinoma versus normal set); the heat maps were
generated based on TCGA expression data for the indicated groups. Blue denotes low expression, and red denotes high expression.
See also Figure S3.
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might be responsible for the early effects of 5-Aza-CdR (Fig-
ure S4). A heat map generated to visualize the detailed DNA
methylation changes of individual probes demonstrated that
DNMT3B knockout reduced the rates of remethylation for the
majority of the rapid rebound genes in group I (Figure 4B). In
addition, the probes in group I dependent on DNMT3B forCrapid remethylation were already methylated in the 3BKO
cells, suggesting that their methylation status was maintained
by DNMT1and/or DNMT3A in the steady state. De novo reme-
thylation of the regions in group I after drug treatment was accel-
erated by the presence of the DNMT3B but not by DNMT3A
or DNMT1. It is interesting that the rate of remethylation was
not strongly influenced by the absence of DNMT1, which isancer Cell 26, 577–590, October 13, 2014 ª2014 Elsevier Inc. 581
Figure 4. Comparison of DNA Methylation
and Gene Expression prior to and after 5-
Aza-CdR Treatment of HCT116 and Deriva-
tive HCT116 1KO and HCT116 3BKO Cells
(A) Line graphs show the median DNA methylation
changes in HCT116, HCT116 1KO, and HCT116
3BKO cells for each group of probes previously
identified in Figure 1.
(B) Heat maps show the remethylation behaviors
of group I probes that were originally heavily
methylated in all three cell lines. Blue means un-
methylated; yellow means fully methylated. The x
axis denotes the days after 5-Aza-CdR treatment.
(C) Median gene expression (Exp) and DNA
methylation changes of group I positively corre-
lated probes and the associated genes in HCT116
and HCT116 3BKO cells.
See also Figure S4.
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sively, as a maintenance enzyme (Jones and Liang, 2009).
We then focused our study on the genes whose body methyl-
ation was positively correlated with gene expression to elucidate
how DNMT3B affected the expression of group I genes. After 5-
Aza-CdR treatment, 210 genes regained body DNA methylation
as well as gene expression in a rapid manner in HCT116 wild-
type cells (Figure 2D). However, DNA methylation and gene
expression levels remained low in 3BKO cells (Figure 4C), sug-
gesting that DNA methylation changes in the gene bodies
caused gene expression changes. A critical additional point
is that the failure of the DNA methylation to rebound shows
that we were observing de novo methylation rather than the582 Cancer Cell 26, 577–590, October 13, 2014 ª2014 Elsevier Inc.outgrowth of cells that were never deme-
thylated in the first place. Together,
these data imply a casual role for 5-Aza-
CdR-induced gene body demethylation
in the downregulation of gene expres-
sion. Fast-rebounding DNA methylation
required DNMT3B and, while it is possible
that it is simply the presence of the protein
that is responsible for the increased
expression, this seems unlikely because
the downregulation of gene expression
was initially seen after the methylation
had been removed by 5-Aza-CdR treat-
ment. Therefore, while neither observa-
tion by itself establishes causality, the
two together strongly suggest that DNA
methylation can lead to increased expres-
sion rather than this being due to the pres-
ence of DNMT3B only.
Decreased DNA Methylation in
Gene Bodies Is Associated with
Increased Chromatin Accessibility,
Occupancy by H2A.Z, and
Alterations of HistoneModifications
We selected two genes, TRIB3 and STC2,
from the fast-rebounding group I fordetailed analysis for expression, histone modifications, histone
variants, and chromatin accessibility in gene body regions after
5-Aza-CdR treatment. The expression of both genes decreased
on 5-Aza-CdR treatment (Figure S5A), and this was accompa-
nied by gene body DNA demethylation at day 5, with increasing
gene body DNA methylation thereafter (Figure 5). Enrichment of
H2A.Z, H3K27m3, and H3K36m3 has been reported in gene
bodies (Coleman-Derr and Zilberman, 2012; Nag et al., 2013;
Venkatesh et al., 2012; Wagner and Carpenter, 2012). Therefore,
we investigated the changes in their focal enrichments (see Fig-
ure S5B for detailed maps on these genes). An increase in H2A.Z
occupancy was observed starting at day 5, peaking at day 24,
and then declining to near-basal levels at day 42 (Figure 5A).
Figure 5. Chromatin Architecture Is Disrup-
ted in Gene Body Regions after 5-Aza-CdR
Treatment
(A) ChIP results for H2A.Z, H3K27m3, and
H3K36m3 before and after 5-Aza-CdR treat-
ment at two representative gene body regions
from group I (top) and two representative gene
body regions from group IV (bottom). Each of
the four panels shows histone modifications on
the left and DNA methylation changes on the
right. Fold enrichment of ChIP data was
normalized to input and compared to control.
Error bars represent SD of the mean from three
independent biological experiments. Regarding
DNA methylation changes, before and after 5-
Aza-CdR treatment, shown on the right side for
each gene: the y axis represents the beta value
of DNA methylation based on data from the
450K Illumina DNA methylation array. For both
data sets: for ChIP and DNA methylation, the x
axis represents the days after 5-Aza-CdR
treatment as indicated.
(B) Column scatter plots indicate the NOMe-
seq results for changes in chromatin accessi-
bility separating the control (Ctrl), the parent
methylated, and daughter demethylated DNA
strands before and after 5-Aza-CdR treatment
at the two representative gene body regions.
The y axis represents the average sizes of
accessible regions where each dot represents
the size of accessible regions in individual
DNA strands as detected by bisulfite sequencing. Error bars represent SD of the mean of the accessible regions from the independent se-
quenced DNA strands. NSD, no significant difference of chromatin accessibility. Bp, base pairs.
See also Figure S5.
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throughout the experiment, whereas H3K36m3 levels decreased
modestly at day 5 and gradually reverted back to the original
level by day 42, echoing the changes in gene expression (Fig-
ure 5A). To potentially explain the different kinetics of remethyla-
tion between groups I and IV, we also performed ChIP assays on
H3K27m3, H3K36m3, and H2A.Z distribution on two selected
genes, NKX1 and SLC18A2, from the slow remethylation group
(group IV) (Figure 5A). We observed similar changes in distribu-
tion of H3K36m3 and H2A.Z in the bodies of these group IV
genes, but dramatically increased levels of H3K27m3 were pre-
sent in the group IV relative to the group I examples (Figure 5A).
This result suggested that the kinetics of remethylation may be
related to the presence or absence of the H3K27m3 mark
following demethylation.
We also used the highly sensitive single-molecule nucleosome
occupancy and methylome sequencing (NOMe-seq) assay
(Kelly et al., 2012) to analyze potential chromatin accessibility
changes in selected regions of TRIB3 and STC2 gene body re-
gions (Figure S5C). We calculated the lengths of accessible re-
gions on the methylated (parent) and demethylated (daughter)
strands before and after treatment for each sequenced strand
and showed accessibility using scatter box plots (Figure 5B).
Although both regions were heavily methylated before treat-
ment, the chromatin architecture was not completely closed in
gene body regions compared to promoter regions. This may
suggest a specific architecture for highly transcribed gene
bodies. Transient exposure to 5-Aza-CdR significantly increasedCthe accessibility on the demethylated (daughter) DNA strands in
both regions at day 5. Consistent with our previous study (Yang
et al., 2012), the DNA strands that remained methylated after
treatment did not show alterations in chromatin accessibility in
both promoters and gene body regions.
Collectively, our results showed that the 5-Aza-CdR treatment
induced gene body demethylation and deposition of H2A.Z and
that it increased accessibility in demethylated DNA regions,
potentially leading to a disruption of chromatin structure. In addi-
tion, the presence or absence of the polycomb mark, H3K27m3,
after treatment might alter remethylation kinetics.
Differential Chromatin Signatures Associated with
Group I and IV Probes
To probe potential mechanisms leading to different DNA reme-
thylation kinetics in more detail, we also tested whether there
is a relationship between pre-existing gene expression levels
and remethylation kinetics among the four groups. The mean
level of preexisting expression of group I genes was the highest,
while the group IV set displayed the lowest mean expression
(Figure S6). These data, together with those shown in Figure 5,
show that chromatin signatures may play a role in maintaining
expression levels in addition to DNAmethylation. Next, we asked
whether the differences in remethylation kinetics between group
I and IV probes might be explained by altered chromatin sig-
natures. For this, we used HCT116 and HCT116-derived DKO1
cells with markedly decreased (95%) DNA methylation engi-
neered by genetic knockdowns of DNMT3B and DNMT1 (Eggerancer Cell 26, 577–590, October 13, 2014 ª2014 Elsevier Inc. 583
(legend on next page)
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Gene Body Methylation Alters Gene Expressionet al., 2006; Rhee et al., 2002). Stable knockdowns were used to
increase the clarity of the analysis. The promoters of both group I
and group IV probes generally showed increases in H3K27m3
and H2.A.Z in the absence of DNA methylation (Figures 6A and
6B), although this was enhanced in the group IV set (Figures
6C and 6D). On the other hand, the bodies of group IV genes
showed a strong enrichment of both H3K27m3 and H2.A.Z
compared to group I in the absence of DNA methylation (Figures
6A–6D). Both of thesemarks are considered antagonistic to DNA
methylation, which might explain why they were refractory to
rebound methylation (Gal-Yam et al., 2008; Kondo et al., 2008;
Zilberman et al., 2008). In contrast, the bodies of group I genes
were marked with H3K36m3 independently of the DNA methyl-
ation level (Figures 6A and 6E), suggesting that this well-known
mark of actively transcribed regions may make them receptive
to remethylation.
Rapidly Remethylating Genes Are Enriched for
Metabolic Processes and Are c-MYC Regulated
We next investigated the functions of the group I and group IV
genes using the ‘‘Metacore’’ commercial program. First, we
analyzed the downregulated genes that displayed gene body de-
methylation after 5-Aza-CdR treatment using gene ontology
(GO) analysis (Table S1). This showed that metabolic processes
and protein catabolic processes were overrepresented in the
group I gene set (Figure 7A). Remarkably, for the slow-rebound-
ing genes (group IV positively correlated genes), seven out of the
ten most significant GO processes were development related
(Figure 7B) and included well-known tumor suppressor genes
such as SFRP1, TXNIP, KL, CHFR, TCF4, PRICKLE1, LTF,
CYGB,GALR1, and PHOX2A. In addition, we incorporated these
two groups of genes in the ‘‘Analyze Network (Transcription Fac-
tors)’’ programofMetaCore to create networks centered on tran-
scription factors (Table S2). These analyses revealed that 56
group I genes either regulated or were regulated by c-MYC
(p = 1.5 3 10144) (Figure 7C). The group IV genes did not
show this enrichment pattern (Figure 7D). Therefore, by altering
gene body DNA methylation, 5-Aza-CdR strongly affected
several well-known tumor-related oncogenic pathways, espe-
cially metabolic pathways and those regulated by c-MYC.
DISCUSSION
The role of DNA methylation in controlling the activities of gene
promoters, whether CpG islands or non-CpG islands, has been
extensively investigated over the past 3 decades (Jones,
2012). These studies have conclusively demonstrated that the
establishment of a closed chromatin state is associated with
the presence of nucleosomes at the transcription start site thatFigure 6. Differential Chromatin Signatures Are Associated with Group
(A and B). Heat maps showing the enrichment of H3K27m3, H3K36m3, and H2A.Z
(B) for group IV. Wiggler was used to normalize the data into a single value for eac
z score was then calculated by transforming the wiggler value in each bin as (Xi X
same bin, and XM and XSD are an average and SD, respectively, of Xi in all of the
z score (Bernstein et al., 2012; Xie et al., 2013).
(C–E) Bar charts showing the distribution of probes across a range of z scores for
z scores for each modification, and the y axes show the number of probes falling
See also Figure S6.
Ceffectively blocks transcription initiation by RNA polymerase II
(Jones and Liang, 2009). The function of gene body DNAmethyl-
ation is poorly understood, although several recent studies have
begun to investigate the potential for how gene body DNA
methylation affects gene expression (Kulis et al., 2012; Lister
et al., 2009; Maunakea et al., 2010; Varley et al., 2013). While it
is well known that the bodies of actively expressed genes,
particularly those located on the active X chromosome, show
increased DNA methylation relative to their inactive counter-
parts, the issue of whether this causally affects transcription
rates has been very difficult to discern (Hellman and Chess,
2007). Our experiments show that gene body DNA methylation
increases gene expression and that the rapid establishment of
this is dependent on the presence of the DNMT3B.
Several reports have suggested that gene body DNA methyl-
ation may increase transcriptional activity by blocking the initia-
tion of intragenic promoters or by affecting the activities of repet-
itive DNAs within the transcriptional unit (Maunakea et al., 2010).
An alternative explanation may be that the formation of an or-
dered structure within the transcribed unit increases the rate of
transcription either by elongation or splicing. It is known that
the nucleosomes in the transcribed region are positioned non-
randomly and are enriched at intron-exon junctions, and the
enrichment of nucleosomes at intron-exon junctions may be
involved in regulating splicing events. Therefore, nucleosome
destabilization in the exon-intron junctions may alter mRNA
levels (Andersson et al., 2009; Luco et al., 2011; Tilgner et al.,
2009). We observed an increase in H2A.Z occupancy and chro-
matin accessibility, especially in the slow-rebounding group IV
probes. The histone variant H2A.Z is mutually exclusive with
DNAmethylation (Edwards et al., 2010; Xiao et al., 2012; Zemach
et al., 2010; Zilberman et al., 2008) and destabilizes nucleo-
somes and mediates nucleosome depletion in contrast to DNA
methylation (Jones and Liang, 2009; Li et al., 2012; Sharma
et al., 2011). In addition, the mark for active transcription elonga-
tion H3K36m3, which we found to be enriched only in the fast re-
methylation group (group I), has been shown to suppress histone
exchange on transcribed genes, thus maintaining the accuracy
and efficiency of transcription (Venkatesh et al., 2012; Wagner
and Carpenter, 2012). This may also explain why the pretreat-
ment expression levels are strongly associated with remethyla-
tion kinetics. Based on our present results and those of others,
gene body DNA demethylationmay lead to nucleosome destabi-
lization in transcribed regions and reduced efficiencies of tran-
scription elongation or splicing.
It is interesting that not all of the gene body probes were posi-
tively correlated with expression as has been reported in other
studies (Kulis et al., 2012; Maunakea et al., 2010; Varley et al.,
2013). A potential explanation is that transcribed regions oftenI and IV Probes
for each category of probes (promoter and gene body) in (A) for group I and in
h genomic position, and mean wiggler value was calculated in a 10 bp bin. The
M)/XSD, where Xi is the experimental wiggler value subtracted by the input in the
bins in the whole genome. Each methylation probe was then correlated with a
H3K27m3 (C), H2A.Z (D), and H3K36m3 (E). The x axes represent the range of
in a particular range of z scores. The z score ofG0 indicates no enrichment.
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Figure 7. GO Analyses of Gene Body Probes that Exhibit a Positive Correlation between DNA Methylation and Gene Expression
(A and B) Top ten significantly enriched cellular processes in group I (A) and group IV (B) probes. The lengths of the orange bars denote significance.
(C and D) Network diagrams indicate the relationship between c-MYC and genes in group I (C) and in group IV (D). Ontology analysis was performed using built-in
functions of MetaCore. The networks are constructed from the basic algorithm ‘‘Analyze Networks (Transcription Factors)’’ of MetaCore (Thomson Reuters). The
genes downregulated by 5-Aza-CdR treatment are marked by a blue solid circle. The other symbols used are as seen on the MetaCore website.
See also Tables S1 and S2.
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hancers, transcription factor binding sites, repetitive elements,
and enrichment of nucleosomes at intron-exon junctions. Most
of these genomic elements are suppressed or stabilized by
DNA methylation, and hypomethylation may therefore result in
their activation and interference with expression of the host
gene. However, the demethylation of these elements is only a
necessary, but not a sufficient, condition for them to regain their
activities, because the presence of transcription factors specific
for these elements (such as highly tissue-specific enhancers) is a
requirement for their reactivation. In addition, we recently re-
ported that only a small percentage of DNA hypomethylated re-
gions gain functionality and chromatin accessibility after 5-Aza-
CdR treatment (Pandiyan et al., 2013). Taken together, gene
repression due to gene body DNA demethylation may be depen-
dent on several key factors, including: (1) whether embedded586 Cancer Cell 26, 577–590, October 13, 2014 ª2014 Elsevier Inc.demethylated functional elements regain activity, (2) whether de-
methylated regions are located at intron-exon junctions together
with destabilized nucleosomes, and (3) possible effects on the
rates of transcript elongation and splicing.
The genes with rapid remethylation in their gene bodies are
associated with increased cellular growth. In addition, these
genes are enriched with metabolic pathway functions or are up-
regulated by c-MYC in uncultured human cancers. These find-
ings are strongly suggestive of an active selection process within
the cultures that allows for the selection for genes that are rapidly
remethylated in their gene bodies’ regions. DNA methyltransfer-
ase inhibitors such as 5-aza-CR and 5-aza-CdR have long been
considered to act as nonspecific inhibitors of DNA methylation
and act primarily by reactivating genes silenced by promoter
methylation. Indeed, we found that transient treatment with low
doses of 5-aza-CdR results in promoter DNA demethylation
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Gene Body Methylation Alters Gene Expressionand gene reexpression. Moreover, the effects of this DNA deme-
thylation are generally more durable than what we observed in
the gene body regions. Thus, the DNA demethylating agents
do not show specificity with respect to their demethylating activ-
ities; however, the remethylation kinetics are very different de-
pending, to a large extent, on the location of CpGs within the
transcriptional unit. The focus on promoter demethylation has
provided insufficient knowledge of the genome-wide effects of
DNA methylation inhibitors (Oki et al., 2007). Our finding sug-
gests a potential role for DNA methylation inhibitors in blunting
the effects of c-MYC, which plays a key role in the pathogenesis
of many human cancers (Dang, 2012). Metabolic reprogramming
is now considered to be one of cancer’s hallmarks because
the metabolites themselves can be oncogenic by altering cell
signaling and blocking cellular differentiation (Hanahan and
Weinberg, 2011; Ward and Thompson, 2012). The c-MYC and
metabolic reprogramming pathways can mutually regulate
each other in producing synergistic oncogenic effects, and inhi-
bition of these activities by bromodomain protein inhibitors
has become an attractive cancer therapeutic target (Butler
et al., 2013; Delmore et al., 2011). We found that the most dra-
matic inhibition of cell growth occurs within the first 2 weeks after
treatment, during the fast rebound period, suggesting that
downregulated genes become upregulated by the ensuing
DNA remethylation, which seems to be dependent on DNMT3B
and the local chromatin structure.
We demonstrate that the DNA remethylation of these tran-
scribed regions is not simply a consequence of gene expression
changes but can increase gene expression levels. Also, selection
of small subpopulations of cells that escaped demethylation af-
ter drug treatment seems unlikely, because the group I genes
failed to remethylate quickly in the 3BKO cells. These findings
do not negate the possibility that the increased DNAmethylation
establishes a feedback loop by which DNA methylation encour-
ages increased gene expression, which in turn, facilitates further
DNA methylation. Murine DNMT3B promotes tumorigenesis
in vivo (Linhart et al., 2007), so DNMT3B could also be a thera-
peutic target to prevent rebound methylation and prolong anti-
tumor effects.
Another surprising result from our study is that most de novo
methylated promoter and gene body regions (group IV) show
sustained DNA demethylation and gene reactivation or downre-
gulation of expression after drug withdrawal. This may explain
the observed long-term antitumor effects in cancer cells after
treatment with DNA methylation inhibitors (Tsai et al., 2012). In
general, those regions seem to be more resistant to remethyla-
tion, possibly because of a chromatin signature in which the
loss of DNA methylation is followed by an enrichment of
H3K27m3marks, which in turn, might block access to DNMT3B.
This may also be due to transcription factor occupancy of reac-
tivated genes and epigenetic switching for silenced genes, since
most of de novo methylated promoter regions are targets of the
polycomb repressive complex (Gal-Yam et al., 2008; Widsch-
wendter et al., 2007).
Taken together, our detailed genome-wide analyses demon-
strate that DNAmethylation inhibitors induce DNAdemethylation
across all genomic features. In addition to the well-known and
well-studied direct activation of tumor suppressor genes, gene
body DNA methylation might be an intriguing additional targetCfor therapy, since it could lead to the downregulation of onco-
genes and metabolic genes. Therefore, these findings will have
direct implications in cancer treatment, not only for the under-
standing of the overall role of DNA methylation in the epigenome
but also in understanding patient’s response to FDA-approved
drugs.
EXPERIMENTAL PROCEDURES
Cell Lines and Drug Treatment
HCT116 WT, HCT116 3BKO, and HCT116 1KO cells were treated with 0.3 mM
of 5-Aza-CdR (Sigma-Aldrich). The medium was changed 24 hr later. All three
cell lines were maintained in McCoy’s 5A medium, supplemented with 10%
fetal bovine serum and 1%penicillin/streptomycin. DNA and RNA purifications
were performed as described elsewhere (Egger et al., 2006).
Colony Formation
Cells were seeded into six-well plates at 1,000 cells per well either with or
without indicated treatment at indicated days. The culture medium was
changed every 3 days. After 10 days of incubation at 37C, cells were washed
with PBS, fixedwith methanol, and stained with 0.5% crystal violet. The colony
formation results are scanned images of six-well plates with indicated
treatment.
Real-Time RT-PCR
Total RNA was isolated from cells using Trizol reagent (Invitrogen) at indi-
cated time points. One microgram of RNA was reverse transcribed using
Moloney murine leukemia virus and random hexamers (Invitrogen). PCR
reactions were performed using KAPA SYBR FAST University 23 qPCR
Master Mix. The sequences of gene-specific primers are available upon
request.
Illumina Infinium HM450 DNA Methylation Assay
The Infinium DNAmethylation assay was performed at the University of South-
ern California Epigenome Center according to the manufacturer’s specifica-
tions (Illumina). The Illumina Infinium HM450 BeadChip examines the DNA
methylation status of 482,421 CpG sites, covering 99% of RefSeq genes
and intergenic regions. The DNA methylation level for each interrogated
CpG site is reported as a beta value, ranging from 0 (not methylated) to 1 (fully
methylated). Downstream processing and beta value calculations were per-
formed as described elsewhere (De Carvalho et al., 2012). Processed genomic
DNAmethylation data sets from primary tissues were downloaded from TCGA
public data portal (http://cancergenome.nih.gov/dataportal/). A description of
TCGA data types, platforms, and analyses are as described elsewhere (De
Carvalho et al., 2012).
NOMe-seq Assay
Nuclei preparation and GpC methyltransferase treatment were performed as
described elsewhere (Kelly et al., 2012). Briefly, freshly extracted nuclei were
treated with 200 U of GpC methyltransferase in the presence of S-adenosyl-
methionine for 15 min at 37C. An equal volume of stop solution (20 nM Tris-
HCl, 600 mM NaCl, 1% SDS, 10 mM EDTA, 400 mg/ml proteinase K) was
added to stop the reaction. The entire reaction mixture was incubated at
55C overnight. DNA was purified by phenol/chloroform extraction and
ethanol precipitation. PCRs were performed using bisulfite-converted DNA,
and the product was cloned using the TOPO TA Cloning Kit (Invitrogen). Indi-
vidual colonies were sequenced to investigate the accessibility and DNA
methylation status of each unique strand. Primer sequences are available on
request. NOMe-seq results were analyzed using Student t tests on GraphPad
Prism version 5 (GraphPad Software).
ChIP and ChIP-Seq Library Generation and Sequencing
ChIP assays were performed as described elsewhere, using commercially
available antibodies (Liang et al., 2004). H3 and H2A.Z antibodies were pur-
chased from Abcam. H3K27m3 and immunoglobulin G antibodies were pur-
chased from Millipore. H3K36m3 antibodies were purchased from Active
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input DNA using a previously described protocol (Kelly et al., 2010b). Samples
were bar coded and sequenced on HiSeq2000 (Illumina) to generate 50 single-
end reads. Sequencing readswere aligned to hg19 using the Burrows-Wheeler
Aligner (http://bio-bwa.sourceforge.net/), and we filtered out nonunique reads
and PCR duplicates. We normalized experimental data into wiggler values
(Bernstein et al., 2012), which were further transformed into z scores to
normalize variations between experiments based on a previously described
method (Xie et al., 2013). In addition, processed HMEC ChIP-seq data sets
can be downloaded from the ENCODE public data portal (https://genome.
ucsc.edu/ENCODE/).
Gene Expression Assay and Statistical Analysis
Expression analysis was performed at the Sanford-Burnham Medical Insti-
tute using the Illumina genome-wide expression BeadChip (HumanHT-
12_V4_0_R1) (Illumina). Gene expression data were processed using the
lumi package in R. The data were log2-transformed and normalized using
robust spline normalization. Comparisons between the control and treated
samples for all three cell lines were performed using the R package limma.
Oncomine (Compendia Bioscience) was used for analysis of publicly
available gene expression data. MetaCore (Thomson Reuters, Version
6.14.61508) was used to identify and visualize biological processes and path-
ways that were enriched due to 5-Aza-CdR treatment. Relevant GO lists are
ranked according to their p value as determined by MetaCore. We performed
this analysis using the default setting, which calculated the p value based on
hypergeometric intersection in comparison to Illumina expression array back-
ground. Please note that the MetaCore GO analysis algorithm only showed
the top ten most enriched cellular processes of the total GO cellular
processes.
Statistical tests were conducted using R software (R version 2.15.2, RDevel-
opment Core Team, http://www.r-project.org/). The ‘‘ConsensusClusterPlus’’
package from Bioconductor was used to cluster DNA methylation probes into
different groups with variant remethylation patterns (Wilkerson and Hayes,
2010). Consensus clustering was performed using amaximum evaluated clus-
ter count (k) of 10 (therefore, cluster counts of 2, 3, 4, 5, 6, 7, 8, 9, and 10 were
evaluated) and 10,000 resamplings with k-means. The R package ‘‘polycor’’
was used to calculate a matrix consisting of Pearson correlations between
DNA methylation and gene expression. The R package ‘‘Gviz’’ was used to
generate genes’ schematic maps. The following CRAN packages were used
to generate plots: ‘‘ggplot2’’ and ‘‘gplots.’’
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